Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beta Bionics, Inc.BBNX · Entity 2350 | Director | May 21, 2026 | May 26, 2026 |
| InspireMD, Inc.NSPR · Entity 7318 | Director | January 14, 2026 | January 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beta Bionics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,209 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 16,965 · Balance 32,209 F1: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.
InspireMD, Inc.
Report date January 14, 2026 · Filed January 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,047 |
Reported balance
After 2026-01-14 transaction · row 1
1 source rowRow 1 · 2026-01-14 · Grant · Acquired 44,030 · Balance 102,047 F1: These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Axonics, Inc.
Report date September 29, 2023 · Filed October 03, 2023
Section 16 reporting ended · disclosed 2023-10-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,777 |
Ending reported balance
After 2023-09-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-09-29 · Exercise / conversion · Acquired 11,250 · Balance 31,452 Row 2 · 2023-09-29 · Sale · Disposed 7,675 · Balance 23,777 F1: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein. F2: This transaction was executed in multiple trades at prices ranging from $56.51 to $57.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-29 · Exercise / conversion · Disposed 11,250 · Balance 0 F3: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023. The units represented here are pro-rated through the date of separation. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.
F2: This transaction was executed in multiple trades at prices ranging from $56.51 to $57.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023. The units represented here are pro-rated through the date of separation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2020 Filed May 14, 2020 21:58 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 20,000 | $0.98 | $19,600.00 |
DisclosureSEC source: 0001562180-20-003646 · primarydocument.xml · nonDerivative · entry 6 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 14, 2020 21:58 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001562180-20-003646 · primarydocument.xml · derivative · entry 10 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,278 Underlying: Common Stock · 15,000 shares Expires 2026-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option vest over a period of four years. 34,346 of the shares subject to the option vested on January 15, 2016 and the remainder vest at a rate of 1/36th per month commencing on January 15, 2017 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| May 11, 2020 Filed May 14, 2020 21:58 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001562180-20-003646 · primarydocument.xml · derivative · entry 9 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,278 Underlying: Common Stock · 15,000 shares Expires 2026-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option vest over a period of four years. 34,346 of the shares subject to the option vested on January 15, 2016 and the remainder vest at a rate of 1/36th per month commencing on January 15, 2017 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| May 11, 2020 Filed May 14, 2020 21:58 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 15,000 | $35.02 | $525,270.00 |
DisclosureSEC source: 0001562180-20-003646 · primarydocument.xml · nonDerivative · entry 5 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,491 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on March 23, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2020 Filed May 14, 2020 21:58 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 1,900 | $34.22 | $65,012.68 |
DisclosureSEC source: 0001562180-20-003646 · primarydocument.xml · nonDerivative · entry 4 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,491 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on March 23, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.65 to $34.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2020 Filed May 14, 2020 21:58 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 13,100 | $34.78 | $455,659.92 |
DisclosureSEC source: 0001562180-20-003646 · primarydocument.xml · nonDerivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,391 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on March 23, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $34.70 to $35.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2020 Filed May 14, 2020 21:58 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 15,000 | $0.98 | $14,700.00 |
DisclosureSEC source: 0001562180-20-003646 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 14, 2020 21:58 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 15,000 | $0.98 | $14,700.00 |
DisclosureSEC source: 0001562180-20-003646 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 20:54 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,147 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001562180-20-002184 · primarydocument.xml · derivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,234 Underlying: Common Stock · 4,147 shares Expires 2026-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option vest over a period of four years. 34,346 of the shares subject to the option vested on January 15, 2016 and the remainder vest at a rate of 1/36th per month commencing on January 15, 2017 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 20:54 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 4,147 | $37.00 | $153,439.00 |
DisclosureSEC source: 0001562180-20-002184 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,535 Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 20:54 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 4,147 | $0.98 | $4,064.06 |
DisclosureSEC source: 0001562180-20-002184 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,147 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001562180-20-003645 · primarydocument.xml · derivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,278 Underlying: Common Stock · 4,147 shares Expires 2026-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person's original Form 4 for this transaction reported that the shares sold by the reporting person where already owned by the reporting person prior to the sale transaction. The shares sold by the reporting person were actually acquired by the reporting person pursuant to the exercise of stock options immediately prior to the sale transaction as reported in Table I and Table II in the amended Form 4. F3 · derivative.exercise_date: The shares subject to the option vest over a period of four years. 34,346 of the shares subject to the option vested on January 15, 2016 and the remainder vest at a rate of 1/36th per month commencing on January 15, 2017 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| March 02, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 4,147 | $37.00 | $153,439.00 |
DisclosureSEC source: 0001562180-20-003645 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,491 F2 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on October 10, 2019. F1 · shares: The reporting person's original Form 4 for this transaction reported that the shares sold by the reporting person where already owned by the reporting person prior to the sale transaction. The shares sold by the reporting person were actually acquired by the reporting person pursuant to the exercise of stock options immediately prior to the sale transaction as reported in Table I and Table II in the amended Form 4. Read SEC document |
| March 02, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 4,147 | $0.98 | $4,064.06 |
DisclosureSEC source: 0001562180-20-003645 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person's original Form 4 for this transaction reported that the shares sold by the reporting person where already owned by the reporting person prior to the sale transaction. The shares sold by the reporting person were actually acquired by the reporting person pursuant to the exercise of stock options immediately prior to the sale transaction as reported in Table I and Table II in the amended Form 4. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:49 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001562180-20-001828 · primarydocument.xml · derivative · entry 4 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,381 Underlying: Common Stock · 8,000 shares Expires 2026-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest over a period of four years. 34,346 of the shares subject to the option vested on January 15, 2016 and the remainder vest at a rate of 1/36th per month commencing on December 15, 2017 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:49 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 7,853 | $37.01 | $290,612.83 |
DisclosureSEC source: 0001562180-20-001828 · primarydocument.xml · nonDerivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,535 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on October 10, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $37.00 to $37.055. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:49 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 8,000 | $37.01 | $296,061.60 |
DisclosureSEC source: 0001562180-20-001828 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,388 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on October 10, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.00 to $37.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:49 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 8,000 | $0.98 | $7,840.00 |
DisclosureSEC source: 0001562180-20-001828 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,853 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001562180-20-003644 · primarydocument.xml · derivative · entry 4 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,425 Underlying: Common Stock · 15,853 shares Expires 2026-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person's original Form 4 for this transaction reported that the shares sold by the reporting person where already owned by the reporting person prior to the sale transaction. The shares sold by the reporting person were actually acquired by the reporting person pursuant to the exercise of stock options immediately prior to the sale transaction as reported in Table I and Table II in the amended Form 4. F5 · derivative.exercise_date: The shares subject to the option vest over a period of four years. 34,346 of the shares subject to the option vested on January 15, 2016 and the remainder vest at a rate of 1/36th per month commencing on December 15, 2017 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| February 26, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 7,853 | $37.01 | $290,612.83 |
DisclosureSEC source: 0001562180-20-003644 · primarydocument.xml · nonDerivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,491 F2 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on October 10, 2019. F1 · shares: The reporting person's original Form 4 for this transaction reported that the shares sold by the reporting person where already owned by the reporting person prior to the sale transaction. The shares sold by the reporting person were actually acquired by the reporting person pursuant to the exercise of stock options immediately prior to the sale transaction as reported in Table I and Table II in the amended Form 4. F4 · price: This transaction was executed in multiple trades at prices ranging from $37.00 to $37.055. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 8,000 | $37.01 | $296,061.60 |
DisclosureSEC source: 0001562180-20-003644 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,344 F2 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on October 10, 2019. F1 · shares: The reporting person's original Form 4 for this transaction reported that the shares sold by the reporting person where already owned by the reporting person prior to the sale transaction. The shares sold by the reporting person were actually acquired by the reporting person pursuant to the exercise of stock options immediately prior to the sale transaction as reported in Table I and Table II in the amended Form 4. F3 · price: This transaction was executed in multiple trades at prices ranging from $37.00 to $37.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 15,853 | $0.98 | $15,535.94 |
DisclosureSEC source: 0001562180-20-003644 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person's original Form 4 for this transaction reported that the shares sold by the reporting person where already owned by the reporting person prior to the sale transaction. The shares sold by the reporting person were actually acquired by the reporting person pursuant to the exercise of stock options immediately prior to the sale transaction as reported in Table I and Table II in the amended Form 4. Read SEC document |
| February 18, 2020 Filed Feb 18, 2020 20:32 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 20,000 | $34.25 | $685,000.00 |
DisclosureSEC source: 0001562180-20-001320 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,388 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on October 10th, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $34.00 to $34.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 18, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 20,000 | $34.25 | $685,000.00 |
DisclosureSEC source: 0001562180-20-003643 · primarydocument.xml · nonDerivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,491 F2 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on October 10th, 2019. F1 · shares: The reporting person's original Form 4 for this transaction reported that the shares sold by the reporting person where already owned by the reporting person prior to the sale transaction. The shares sold by the reporting person were actually acquired by the reporting person pursuant to the exercise of stock options immediately prior to the sale transaction as reported in Table I and Table II in the amended Form 4. F3 · price: This transaction was executed in multiple trades at prices ranging from $34.00 to $34.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 20:32 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 103 | $34.00 | $3,502.00 |
DisclosureSEC source: 0001562180-20-001320 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,388 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on October 10th, 2019. Read SEC document |
| February 13, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,103 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001562180-20-003643 · primarydocument.xml · derivative · entry 4 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,278 Underlying: Common Stock · 20,103 shares Expires 2026-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person's original Form 4 for this transaction reported that the shares sold by the reporting person where already owned by the reporting person prior to the sale transaction. The shares sold by the reporting person were actually acquired by the reporting person pursuant to the exercise of stock options immediately prior to the sale transaction as reported in Table I and Table II in the amended Form 4. F4 · derivative.exercise_date: The shares subject to the option vest over a period of four years. 34,346 of the shares subject to the option vested on January 15, 2016 and the remainder vest at a rate of 1/36th per month commencing on January 15, 2017 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| February 13, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 103 | $34.00 | $3,502.00 |
DisclosureSEC source: 0001562180-20-003643 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,491 F2 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on October 10th, 2019. F1 · shares: The reporting person's original Form 4 for this transaction reported that the shares sold by the reporting person where already owned by the reporting person prior to the sale transaction. The shares sold by the reporting person were actually acquired by the reporting person pursuant to the exercise of stock options immediately prior to the sale transaction as reported in Table I and Table II in the amended Form 4. Read SEC document |
| February 13, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 20,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-003643 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person's original Form 4 for this transaction reported that the shares sold by the reporting person where already owned by the reporting person prior to the sale transaction. The shares sold by the reporting person were actually acquired by the reporting person pursuant to the exercise of stock options immediately prior to the sale transaction as reported in Table I and Table II in the amended Form 4. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 21:04 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 8,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-000791 · primarydocument.xml · derivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: All of the Performance Based Restricted Stock Units vested on January 30, 2020. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 21:04 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-000791 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 20:53 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 20,000 | $31.46 | $629,156.00 |
DisclosureSEC source: 0001562180-20-000595 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,491 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on October 10th, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $31.16 to $31.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 23, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001562180-20-003642 · primarydocument.xml · derivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,381 Underlying: Common Stock · 20,000 shares Expires 2026-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest over a period of four years. 34,346 of the shares subject to the option vested on January 15, 2016 and the remainder vest at a rate of 1/36th per month commencing on January 15, 2017 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. F3 · balance_after: The reporting person's original Form 4 for this transaction reported that the shares sold by the reporting person where already owned by the reporting person prior to the sale transaction. The shares sold by the reporting person were actually acquired by the reporting person pursuant to the exercise of stock options immediately prior to the sale transaction as reported in Table I and Table II in the amended Form 4. Read SEC document |
| January 23, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 20,000 | $31.46 | $629,156.00 |
DisclosureSEC source: 0001562180-20-003642 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,491 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on October 10th, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $31.16 to $31.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: The reporting person's original Form 4 for this transaction reported that the shares sold by the reporting person where already owned by the reporting person prior to the sale transaction. The shares sold by the reporting person were actually acquired by the reporting person pursuant to the exercise of stock options immediately prior to the sale transaction as reported in Table I and Table II in the amended Form 4. Read SEC document |
| January 23, 2020 Filed May 14, 2020 21:58 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-003642 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 17:56 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 30,000 | $26.07 | $782,109.00 |
DisclosureSEC source: 0001562180-19-006255 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,491 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on October 10th, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.8 to $26.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 20:41 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $25.82 | $0.00 |
DisclosureSEC source: 0001562180-19-006116 · primarydocument.xml · derivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2029-12-12 F3 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 12, 2023, provided the reporting person remains in continuous service on each vesting date. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 20:41 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantPerformance-Based Restricted Stock Units · Derivative | 13,043 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-006116 · primarydocument.xml · derivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,043 Underlying: Common Stock · 13,043 shares Expires not disclosed F2 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2021, and provided the reporting person remains in continuous service through December 31, 2021. F2 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2021, and provided the reporting person remains in continuous service through December 31, 2021. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 20:41 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantPerformance-Based Restricted Stock Units · Derivative | 13,043 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-006116 · primarydocument.xml · derivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,043 Underlying: Common Stock · 13,043 shares Expires not disclosed F1 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2020 and provided the reporting person remains in continuous service through December 31, 2020. F1 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2020 and provided the reporting person remains in continuous service through December 31, 2020. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 16:08 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 30,000 | $21.61 | $648,225.00 |
DisclosureSEC source: 0001562180-19-005695 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,491 F1 · kind: This sale was pursuant to a 10b5-1 plan adopted by the reporting person on October 10th, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.50 to $22.115. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 20:42 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 30,000 | $20.74 | $622,050.00 |
DisclosureSEC source: 0001562180-19-005639 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,491 F1 · price: The shares were sold in a public offering pursuant to the Registration Statement of Axonics Modulation Technologies, Inc. on Form S-3 (File No. 333-234546) Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 21:34 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantPerformance-Based Restricted Stock Units · Derivative | 8,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-002371 · doc4.xml · derivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires not disclosed F3 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2020, and provided the reporting person remains in continuous service through January 30, 2021. F3 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2020, and provided the reporting person remains in continuous service through January 30, 2021. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 21:34 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantPerformance-Based Restricted Stock Units · Derivative | 8,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-002371 · doc4.xml · derivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires not disclosed F2 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2019 and provided the reporting person remains in continuous service through January 30, 2020. F2 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2019 and provided the reporting person remains in continuous service through January 30, 2020. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 21:34 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantStock Option (Right to Buy) · Derivative | 106,667 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0000899243-19-002371 · doc4.xml · derivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,667 Underlying: Common Stock · 106,667 shares Expires 2029-01-30 F1 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 30, 2023, provided the reporting person remains in continuous service on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.